Hoffmann-la Roche Inc.

Anadys Pharmaceuticals, Inc.

Klaus B Simonsen

Stephen Evan Webber

Binh Vu

Gregory Jay Haley

Nader Fotouhi

Norman Kong

Vlad Edward Gregor

Douglas Eric Murphy

Dionisios Vourloumis

Emily Aijun Liu

Yuefen Zhou

Zhongxiang Sun

Thomas C Hermann

Geoffrey C Winters

Benjamin Ayida

and the pharmaceutically acceptable salts and esters thereof, wherein X, X, X, Y, Yand R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.

Chiral cis-imidazolines

There are provided compounds of the formula I wherein R, V, Vand Ring A are described herein. The compounds exhibit anticancer activity.

Cis-imidazolines

There are presented compounds of the formula or pharmaceutically acceptable salts thereof,wherein Y, Y, X, X, Xand R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.

The present invention provides compounds according to formula I having the designations provided herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

The invention relates to antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds and pharmaceutical compositions thereof. This invention also relates to a method of using such compounds in the treatment of bacterial infections in mammals, especially humans.

Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds

Growing community of inventors

Frederiksberg, Denmark

Klaus B Simonsen